Elopag 50 mg contains eltrombopag, an oral thrombopoietin receptor agonist used to help increase platelet counts in specific blood disorders. It is manufactured by Everest Pharmaceuticals Ltd. and is available as a prescription tablet. Eltrombopag is used in selected patients with persistent or chronic immune thrombocytopenia (ITP), thrombocytopenia associated with chronic hepatitis C, and severe aplastic anemia. The exact indication, starting dose, and treatment plan depend on the patient’s condition and clinical factors.

Elopag 50 mg should not be treated as a general medicine for low platelets. A healthcare professional must determine why the platelet count is low before treatment begins. Regular blood counts and liver tests are also important during therapy. This page provides educational information about Elopag 50 mg. It does not replace the prescribing information or advice from your hematologist, oncologist, or other qualified healthcare professional.

Product detail	Information
Brand name	Elopag
Generic name	Eltrombopag
Strength	50 mg
Active ingredient	Eltrombopag olamine
Dosage form	Tablet
Drug class	Thrombopoietin receptor agonist
Therapeutic area	Hematology
Manufacturer	Everest Pharmaceuticals Ltd.
Product type	Prescription medicine

Everest Pharmaceuticals lists Elopag 50 among its hematology products as Eltrombopag INN 50 mg.

Understanding the Mechanism and Usage

Eltrombopag belongs to the thrombopoietin receptor agonist class. Thrombopoietin is a natural signal involved in platelet production. Eltrombopag binds to the thrombopoietin receptor and activates signaling involved in the growth and development of platelet-producing cells. The practical result is increased platelet production. The medicine does not work by directly replacing platelets. Instead, it encourages the bone marrow to produce more platelets. The FDA prescribing information describes eltrombopag as a thrombopoietin receptor agonist and recommends using the lowest dose needed to achieve the appropriate platelet response.

What diseases does Elopag treat?

Elopag 50 mg may be prescribed for specific forms of thrombocytopenia. Persistent or chronic immune thrombocytopenia: Eltrombopag is used in adults and children aged 1 year and older with ITP who have not responded adequately to corticosteroids, immunoglobulins, or splenectomy. It is intended for patients whose platelet level and clinical condition create a bleeding risk.

Chronic hepatitis C-associated thrombocytopenia: Eltrombopag may be used to increase platelet counts when thrombocytopenia prevents the initiation or continuation of interferon-based therapy. Severe aplastic anemia: It may be used with standard immunosuppressive therapy as first-line treatment in appropriate patients. It can also be used for severe aplastic anemia after an insufficient response to immunosuppressive therapy. Eltrombopag is not indicated for myelodysplastic syndromes.

Benefits of Elopag 50 mg

The potential therapeutic benefit comes from increasing platelet production.

Depending on the indication, treatment may help:

• Increase platelet counts
• Reduce the risk associated with clinically important thrombocytopenia
• Support treatment plans that require a safer platelet level
• Reduce the need for some platelet-supportive interventions in selected patients

The treatment goal is not necessarily to produce a normal platelet count. The prescribing information recommends using the lowest effective dose needed to maintain an appropriate platelet response.

Who Can Take Elopag?

Eligibility depends on the diagnosis and the prescribing healthcare professional.

Eltrombopag has labeled uses in:

• Adults with appropriate indications
• Children with persistent or chronic ITP from 1 year of age
• Selected patients with severe aplastic anemia
• Adults with chronic hepatitis C-associated thrombocytopenia in the labeled treatment setting

Age requirements and dosing vary by indication. Therefore, patients should not assume that the 50 mg tablet is appropriate simply because it is available.

Who Should Not Use It?

The prescribing information lists no absolute contraindications for eltrombopag. However, this does not mean the medicine is suitable for everyone.

Tell your healthcare professional if you have:

• Liver disease
• A history of blood clots
• Abnormal liver tests
• Cataracts or vision problems
• A blood or bone marrow disorder
• Pregnancy or plans to become pregnant
• A need for breastfeeding
• Other medicines or supplements

Your doctor will determine whether the potential benefit outweighs the risks.

Dosage of Elopag 50 mg

The correct dose depends on the condition being treated. For persistent or chronic ITP, the labeled starting dose for most adults and children aged 6 years and older is 50 mg once daily. Children aged 1 to 5 years generally start at 25 mg once daily. Lower starting doses may apply to patients with hepatic impairment or certain East or Southeast Asian ancestry.

For chronic hepatitis C-associated thrombocytopenia, the labeled starting dose is 25 mg once daily, with adjustments based on platelet response. For refractory severe aplastic anemia, the labeled adult starting dose is 50 mg once daily, with lower starting doses in certain patients. First-line severe aplastic anemia has a different dosing regimen and may involve substantially higher doses under specialist supervision. Do not use this information to select your personal dose. Your doctor should determine the dose and adjust it according to platelet counts, liver function, treatment response, and the indication.

How to Take Elopag 50 mg

Take Elopag exactly as prescribed. The tablet should generally be taken without food or with a meal containing low calcium. Eltrombopag can bind to polyvalent minerals in the digestive tract. These include calcium, iron, magnesium, and aluminum. The prescribing information recommends taking eltrombopag at least 2 hours before or 4 hours after medicines or products containing polyvalent cations. This includes many antacids, mineral supplements, and calcium-rich foods. Swallow the tablet according to the product instructions. Do not change the timing or dose without discussing it with your healthcare professional.

What Happens if You Miss a Dose?

If you forget a dose, follow your prescriber’s missed-dose instructions. Do not take two doses together unless your healthcare professional specifically tells you to do so. The prescribing information states that patients should not receive more than one dose within a 24-hour period.

Possible Side Effects of Elopag

Eltrombopag can cause side effects. Common adverse reactions reported across indications include:

• Nausea
• Headache
• Diarrhea
• Fatigue
• Cough
• Fever
• Anemia
• Increased alanine aminotransferase

The exact side-effect profile can vary according to the underlying condition and treatment combination. Not every patient experiences these effects.

Serious Side Effects

Liver-related problems

Eltrombopag can cause serious liver injury. Patients may need liver-function testing before treatment and during therapy. The risk requires particular attention in patients with chronic hepatitis C. Contact your healthcare professional promptly if you develop symptoms that could indicate liver problems, such as unusual yellowing of the skin or eyes, dark urine, severe abdominal discomfort, or unusual weakness.

Blood clots

Eltrombopag can increase the risk of thrombotic or thromboembolic complications. Portal vein thrombosis has been reported in patients with chronic liver disease receiving eltrombopag. Platelet counts should therefore be monitored regularly.

Seek urgent medical attention for symptoms such as:

• Sudden chest pain
• Shortness of breath
• Sudden weakness
• New difficulty speaking
• Severe or unexplained leg swelling
• Sudden severe headache

Cataracts

Cataracts have been reported with eltrombopag therapy.

Tell your doctor about new or worsening vision problems.

Drug Interactions

Eltrombopag has clinically important interaction considerations.

Calcium, iron, magnesium and aluminum

These polyvalent cations can reduce eltrombopag absorption.

This includes certain:

• Antacids
• Calcium supplements
• Iron supplements
• Magnesium supplements
• Mineral supplements
• Calcium-rich foods

Follow the recommended separation interval of 2 hours before or 4 hours after these products.

Other medicines

Eltrombopag can also interact with certain medicines through transporter pathways. Tell your healthcare professional about every prescription medicine, over-the-counter product, vitamin, mineral, and herbal supplement you use. Do not stop another medicine because of a possible interaction without professional advice.

Foods to Avoid While Taking Elopag

The most important dietary consideration is calcium. Take eltrombopag without food or with a low-calcium meal according to the prescribing instructions. Keep calcium-rich foods and polyvalent-cation products within the recommended separation window.

Examples can include:

• Milk
• Yogurt
• Calcium-fortified foods
• Mineral supplements

Your pharmacist can help you create a convenient daily schedule.

Pregnancy and Breastfeeding

Tell your healthcare professional if you are pregnant, planning pregnancy, or breastfeeding. The prescribing information advises women not to breastfeed during treatment. The decision to use eltrombopag during pregnancy requires individualized medical assessment. Do not stop treatment on your own.

Monitoring During Treatment

Monitoring is an important part of eltrombopag therapy.

Your healthcare professional may monitor:

• Platelet count
• Complete blood count
• Liver function
• Liver enzymes
• Bilirubin
• Treatment response
• Signs of thrombosis
• Other disease-specific laboratory findings

For ITP, the prescribing information recommends weekly CBC monitoring until a stable platelet count is reached, followed by monthly monitoring. Monitoring schedules can differ by indication.

Clinical Evidence Supporting Eltrombopag

Eltrombopag has been studied across several hematologic conditions. The FDA-approved prescribing information includes clinical-study data for persistent or chronic ITP, chronic hepatitis C-associated thrombocytopenia, and severe aplastic anemia. Importantly, clinical evidence for the active ingredient should not automatically be presented as proof of a specific manufacturer’s product quality unless product-specific evidence supports that statement. This distinction improves transparency and medical credibility.

Genetic and Clinical Factors Before Starting Treatment

Genetic testing is not routinely required for every patient before starting eltrombopag. However, ancestry can influence eltrombopag exposure and may affect starting-dose decisions in certain indications. The prescribing information specifically identifies East and Southeast Asian ancestry as a factor requiring dose consideration. For that reason, your doctor should know your relevant medical and demographic history before choosing a dose.

Available Strengths

Eltrombopag products can be available in several strengths depending on the manufacturer and market.

The current U.S. prescribing information lists tablet strengths of:

• 12.5 mg
• 25 mg
• 50 mg
• 75 mg

For the product discussed on this page, the supplied product information identifies Elopag 50 mg as the 50 mg tablet. Other Elopag strengths may also be marketed. Everest Pharmaceuticals’ product catalogue lists both Elopag 25 and Elopag 50.

Available Pack Sizes

Pack sizes can vary by market. Current Bangladesh medicine listings identify Elopag 50 mg in 7-tablet and 14-tablet configurations, while some international supplier pages list 28 tablets. Always confirm the exact pack size before ordering.

Storage Instructions

Follow the storage instructions printed on the product packaging and manufacturer’s prescribing information.

Keep the medicine:

• In its original packaging
• Away from excessive moisture
• Away from direct heat
• Out of children’s reach

Do not use tablets after the expiry date.

Manufacturer Information

Everest Pharmaceuticals Ltd. lists Elopag 50 as Eltrombopag INN 50 mg within its hematology product portfolio. The manufacturer should always be checked against the actual product packaging before use.

Global Access and Knowledge Bridge Through Selxen

Selxen is positioned as a global access and knowledge bridge for patients and healthcare professionals seeking information about prescription medicines.

For Elopag 50 mg, the focus should be on helping patients understand:

• The active ingredient
• Manufacturer
• Strength
• Prescription status
• Safe administration
• Product availability
• Required documentation
• Appropriate medical supervision

International medicine supply can be subject to local prescribing, pharmacy, customs, and import rules. Availability should therefore be confirmed before an order is placed.

Why Buy Elopag 50 mg From Us?

A responsible medicine supplier should offer more than a product listing.

Customers should expect:

• Clear product identification
• Manufacturer transparency
• Prescription verification
• Secure ordering
• Appropriate packaging
• Availability confirmation
• Customer support
• Clear shipping information
• A documented authenticity process

Where applicable, provide batch number, expiry date, packaging photographs, and manufacturer details for verification. Avoid claims such as “100% genuine,” “FDA approved,” or “WHO-GMP certified” unless the specific claim can be documented for the exact product and supply chain.

Shipping and Delivery

Prescription medicines require careful handling during fulfillment.

Before ordering, customers should confirm:

1. Product availability
2. Pack size
3. Prescription requirements
4. Shipping destination
5. Estimated delivery timeframe
6. Applicable import or customs requirements

Delivery times can vary by country, courier, customs processing, and product availability. A trustworthy supplier should communicate realistic timelines rather than guaranteeing delivery that it cannot control.

Authenticity Guarantee

Product authenticity should be supported by a transparent verification process.

Customers should check:

• Brand name
• Generic name
• Strength
• Manufacturer
• Batch number
• Expiry date
• Packaging integrity
• Product appearance
• Any manufacturer verification feature

Do not use damaged, opened, or suspiciously labeled medicine. If the packaging does not match the prescription or product information, contact the dispensing pharmacy before taking the medicine.

Prescription Requirements

Elopag 50 mg is a prescription medicine. It should be used only under appropriate medical supervision.

A valid prescription helps confirm:

• The intended indication
• Appropriate dose
• Treatment duration
• Relevant patient factors
• Monitoring requirements

A pharmacy should not encourage self-medication with eltrombopag.

Advantages of Elopag 50 mg

Potential practical advantages include:

• Oral tablet administration
• Established therapeutic role for selected thrombocytopenic conditions
• Availability in a 50 mg strength
• Manufacturer identification
• Established eltrombopag prescribing guidance
• Potential usefulness when platelet production needs to be increased

These advantages do not mean the medicine is appropriate for every patient.

Limitations of Elopag 50 mg

Elopag has important limitations.

It is not a general treatment for every cause of thrombocytopenia.

It should not be used to normalize platelet counts.

It requires laboratory monitoring.

It may affect liver function.

It can increase the risk of thrombotic complications.

It also has clinically important food and drug interaction considerations.

These limitations make specialist supervision essential.

When to Contact Your Doctor

Contact your healthcare professional if:

• Your platelet count changes unexpectedly
• You develop unusual bleeding
• You develop symptoms of a blood clot
• You notice yellowing of the skin or eyes
• You develop significant abdominal symptoms
• You experience new vision changes
• You develop severe or persistent side effects
• You accidentally take more than prescribed

For severe chest pain, difficulty breathing, sudden neurological symptoms, or another medical emergency, seek immediate emergency care.

Conclusion

Elopag 50 mg (Eltrombopag) is a prescription thrombopoietin receptor agonist used in selected patients with persistent or chronic immune thrombocytopenia, chronic hepatitis C-associated thrombocytopenia, and severe aplastic anemia. Its use requires more than choosing a 50 mg tablet. The correct dose depends on the indication, age, platelet response, liver function, and other patient factors. Eltrombopag also requires careful attention to calcium and other polyvalent cations, regular laboratory monitoring, and awareness of liver and clotting risks. For patients seeking Elopag 50 mg, the safest approach is to confirm the prescription, manufacturer, strength, pack size, availability, and product authenticity before purchase.

FAQs

What is Elopag 50 mg used for?

Elopag 50 mg contains eltrombopag. It is used for selected patients with persistent or chronic immune thrombocytopenia, severe aplastic anemia, and certain cases of hepatitis C-associated thrombocytopenia.

Is Elopag 50 mg the same as eltrombopag?

Elopag is a brand name, while eltrombopag is the active ingredient. The supplied manufacturer information identifies Elopag 50 as eltrombopag 50 mg.

How does eltrombopag work?

Eltrombopag stimulates the thrombopoietin receptor. This activates signaling that promotes the development of platelet-producing cells and can increase platelet production.

Is 50 mg the usual dose of eltrombopag?

It can be the starting dose for many adults and children aged 6 years or older with ITP. However, other conditions and patient factors use different doses. Never choose the dose based only on tablet strength.

Can I take calcium with Elopag 50 mg?

Calcium can reduce eltrombopag absorption. The prescribing information recommends taking eltrombopag at least 2 hours before or 4 hours after products containing polyvalent cations.

What are common side effects of eltrombopag?

Reported adverse reactions include nausea, diarrhea, headache, fatigue, cough, fever, anemia, and increased liver enzymes.

Does Elopag require blood tests?

Yes. Platelet counts and other laboratory tests are monitored during treatment. Liver function monitoring is also important because eltrombopag can cause hepatotoxicity.